Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life

We assessed the safety of allergoid adjuvanted by monophosphoryl lipid A (uSCIT-MPL-4) in a real-life setting. Patients treated with uSCIT-MPL-4 were followed-up for 1 year. Systemic reactions (SRs) were registered and the association with potential risk factors was evaluated. 2929 patients were inc...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2019-06, Vol.11 (9), p.783-794
Main Authors: Caminati, Marco, Arcolaci, Alessandra, Guerriero, Massimo, Manzotti, Giuseppina, Crivellaro, Mariangiola, Rolla, Giovanni, Fassio, Filippo, Senna, Gianenrico
Format: Article
Language:English
Subjects:
adjuvants
allergic asthma
allergic rhinitis
Allergies
Asthma
Classification
Gender
Immunotherapy
Lipid A
Lipids
local reactions
Monophosphoryl lipid A
Patients
Risk factors
safety
Statistical analysis
Studies
subcutaneous immunotherapy
systemic reaction grading system
systemic reactions
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We assessed the safety of allergoid adjuvanted by monophosphoryl lipid A (uSCIT-MPL-4) in a real-life setting. Patients treated with uSCIT-MPL-4 were followed-up for 1 year. Systemic reactions (SRs) were registered and the association with potential risk factors was evaluated. 2929 patients were included. Grade 0, 1, 2, 3 and 4 SR reactions were observed respectively in 3.3, 1.5, 0.31, 0.07 and 0.07% of patients. A significant association was detected between Grade ≥1 SRs and: female gender, number of administrations, previous local reactions. uSCIT-MPL-4 is safe. Local reactions should be accurately assessed as they may represent a risk factor for Grade ≥1 SRs, together with gender and number of doses/year.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2019-0009